Background Andexanet alfa is a modified recombinant inactive form of human factor Xa
developed for reversal of factor Xa inhibitors. Methods We evaluated 352 patients who had …

Background Andexanet alfa (andexanet) is a recombinant modified human factor Xa decoy
protein that has been shown to reverse the inhibition of factor Xa in healthy volunteers …

Background: Andexanet alfa is a modified recombinant inactive factor Xa (FXa) designed to
reverse FXa inhibitors. ANNEXA-4 (Andexanet Alfa, a Novel Antidote to the Anticoagulation …

Background Bleeding is a complication of treatment with factor Xa inhibitors, but there are no
specific agents for the reversal of the effects of these drugs. Andexanet is designed to …

Background Patients with acute intracerebral hemorrhage who are receiving factor Xa
inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that …

An ability to readily determine an anticoagulant effect with an emerging class of direct, active
site, oral factor Xa inhibitors is viewed by the medical community as attractive and by some …

Abstract Background Direct factor Xa inhibitors have demonstrated compelling anticoagulant
efficacy and/or safety profiles across multiple diverse patient populations. A specific antidote …

Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …

Background: Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late‐
stage clinical development for the prevention and treatment of thromboembolic diseases …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …